Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NM21 1480

Next Previous
X
Search
Drug Profile

NM21 1480

Alternative Names: 4-1BB/PD-L1/HSA trispecific MATCH3 antibody - Numab; Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody - Numab; CS-2006; NM21-1480; PD-L1/4-1BB/HSA trispecific scDb-scFv - Numab; Trispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) single-chain Fv fusion protein - Numab

Latest Information Update: 22 May 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Numab
  • Developer CStone Pharmaceuticals; Numab
  • Class Antineoplastics; Immunoglobulin Fv fragments; Immunotherapies; Recombinant fusion proteins; Trispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 08 Apr 2022 Pharmacodynamics data from preclinical studies in Solid tumours were presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
  • 15 Sep 2021 Preclinical trials in Solid tumours in China (Parenteral)
  • 15 Sep 2021 CStone Pharmaceuticals plans a clinical trial in Solid tumours (Late-stage disease) in China

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top